Lexicon Pharmaceuticals (LXRX) Tops 4Q Forecasts

Lexicon Pharmaceuticals, Inc. (LXRX) shares are up more than 5% to $1.03  in pre-market trading Wednesday after the company reported its fourth quarter earnings results.

The biopharmaceutical firm reported EPS of $0.00 on revenues of $21.5 million, up 1435.7% from a year ago. Analysts were expecting EPS of ($0.03) on revenues of $10.31 million. R&D expenses came one percent lower to $20.0 million from $20.3 million yoy.

For the year ended December 31, 2014, Lexicon said revenues increased to $22.9 million from $2.2 million for the corresponding period in 2013.

On valuation measures, Lexicon Pharmaceuticals Inc. shares, which currently have an average 3-month trading volume of 1.78 million shares, trade with a P/E to growth ratio of (0.15). The median Wall Street price target on the name is $3.00. Currently ticker boasts 6 ‘Buy’ endorsements, compared to 2 ’Holds’ and no ‘Sell’.

Profitability-wise, LXRX has a t-12 operating margin of (3,593%). The $504.43 million market cap company reported $339.30 million in cash vs. $107.6 million in debt in its most recent quarter.

LXRX currently prints a one year loss of about 44.00% and a year-to-date return of around 7.70%.

The chart below shows where the equity has traded over the last 52 weeks.

Lexicon Pharmaceuticals Inc. focuses on the development of treatments for human disease. The company was founded in 1995 and is headquartered in The Woodlands, Texas.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.